Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Von Hippel-Lindau mutations disrupt vascular patterning and maturation via Notch
Alexandra Arreola, … , W. Kimryn Rathmell, John C. Chappell
Alexandra Arreola, … , W. Kimryn Rathmell, John C. Chappell
Published February 22, 2018
Citation Information: JCI Insight. 2018;3(4):e92193. https://doi.org/10.1172/jci.insight.92193.
View: Text | PDF
Research Article Oncology Vascular biology

Von Hippel-Lindau mutations disrupt vascular patterning and maturation via Notch

  • Text
  • PDF
Abstract

Von Hippel-Lindau (VHL) gene mutations induce neural tissue hemangioblastomas, as well as highly vascularized clear cell renal cell carcinomas (ccRCCs). Pathological vessel remodeling arises from misregulation of HIFs and VEGF, among other genes. Variation in disease penetrance has long been recognized in relation to genotype. We show Vhl mutations also disrupt Notch signaling, causing mutation-specific vascular abnormalities, e.g., type 1 (null) vs. type 2B (murine G518A representing human R167Q). In conditional mutation retina vasculature, Vhl-null mutation (i.e., UBCCreER/+Vhlfl/fl) had little effect on initial vessel branching, but it severely reduced arterial and venous branching at later stages. Interestingly, this mutation accelerated arterial maturation, as observed in retina vessel morphology and aberrant α-smooth muscle actin localization, particularly in vascular pericytes. RNA sequencing analysis identified gene expression changes within several key pathways, including Notch and smooth muscle cell contractility. Notch inhibition failed to reverse later-stage branching defects but rescued the accelerated arterialization. Retinal vessels harboring the type 2B Vhl mutation (i.e., UBCCreER/+Vhlfl/2B) displayed stage-specific changes in vessel branching and an advanced progression toward an arterial phenotype. Disrupting Notch signaling in type 2B mutants increased both artery and vein branching and restored arterial maturation toward nonmutant levels. By revealing differential effects of the null and type 2B Vhl mutations on vessel branching and maturation, these data may provide insight into the variability of VHL-associated vascular changes — particularly the heterogeneity and aggressiveness in ccRCC vessel growth — and also suggest Notch pathway targets for treating VHL syndrome.

Authors

Alexandra Arreola, Laura Beth Payne, Morgan H. Julian, Aguirre A. de Cubas, Anthony B. Daniels, Sarah Taylor, Huaning Zhao, Jordan Darden, Victoria L. Bautch, W. Kimryn Rathmell, John C. Chappell

×

Figure 3

In P7 mouse retina, conditional Vhl-null and –type 2B mutations accelerate vessel maturation via excess alpha-smooth muscle actin expression, and this defect can be rescued by blocking Notch signaling.

Options: View larger image (or click on image) Download as PowerPoint
In P7 mouse retina, conditional Vhl-null and –type 2B mutations accelera...
(A–H) Representative images of P7 mouse retinal vasculature stained with isolectin B4 (top rows) and αSMA (middle rows). A quarter region, or leaflet, is shown for UBC+/+Vhlfl/fl, UBC+/+Vhlfl/2B, UBCCreER/+Vhlfl/fl, and UBCCreER/+Vhlfl/2B littermate retinas exposed to tamoxifen and subjected to either control treatment (DMSO, A–D) or Notch inhibition (DAPT, E–H). Scale bars: 200 μm. (I) Percent length of primary artery covered by αSMA+ cells in control (triangles) and Notch-inhibited (squares) P7 vascular networks. *P ≤ 0.05 vs. control UBC+/+Vhlfl/fl and UBC+/+Vhlfl/2B, and vs. Notch-inhibited within same genotype. (J) Diameter of primary retinal artery measured from control (triangles) and Notch-inhibited (squares) P7 vascular networks. *P ≤ 0.05 vs. control UBC+/+Vhlfl/fl and UBC+/+Vhlfl/2B, and vs. Notch-inhibited within same genotype. (K) Percent mislocalization of αSMA expression not associated with primary retinal arteries in control (triangles) and Notch-inhibited (squares) retinas. *P ≤ 0.05 vs. control UBC+/+Vhlfl/fl and UBC+/+Vhlfl/2B, and vs. Notch-inhibited within same genotype. **P ≤ 0.05 vs. control UBC+/+Vhlfl/fl, and vs. Notch-inhibited UBC+/+Vhlfl/2B. Values are averages ± SEM. n = 6–8 retina images per group (i.e., 3–4 from 2 experimental litters). All statistical comparisons performed using 1-way ANOVA followed by pair-wise comparisons with a 2-tailed Student t test.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts